Edition:
United Kingdom

ContraVir Pharmaceuticals Inc (CTRV.OQ)

CTRV.OQ on NASDAQ Stock Exchange Capital Market

0.34USD
13 Dec 2017
Change (% chg)

$-0.01 (-3.57%)
Prev Close
$0.35
Open
$0.37
Day's High
$0.37
Day's Low
$0.32
Volume
127,845
Avg. Vol
191,987
52-wk High
$2.06
52-wk Low
$0.32

Chart for

About

ContraVir Pharmaceuticals, Inc. is focused on curing hepatitis B through the combination of direct and indirect acting antiviral compounds. Its two assets tenofovir exalidex, or TXL, and CRV431 have complementary mechanisms of action and have shown potential synergy against hepatitis B virus (HBV). TXL is designed to deliver... (more)

Overall

Beta: 1.54
Market Cap(Mil.): $48.36
Shares Outstanding(Mil.): 78.00
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Contravir Pharmaceuticals adjourns annual meeting of stockholders until Dec 21

* CONTRAVIR PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING OF STOCKHOLDERS UNTIL DECEMBER 21, 2017

13 Dec 2017

BRIEF-Contravir Pharmaceuticals enters research collaboration with Li Ka Shing Institute of Virology

* Contravir Pharmaceuticals announces research collaboration agreement with Li Ka Shing Institute of Virology Source text for Eikon: Further company coverage: (Reporting by Sruthi Ramakrishnan)

17 Oct 2017

BRIEF-Contravir Pharmaceuticals receives HBV IND approval for tenofovir exalidex in the U.S.

* Contravir Pharmaceuticals receives hbv ind approval for tenofovir exalidex (txl™) in the United States

11 Sep 2017

BRIEF-U.K. accepts Contravir Pharma's clinical trial application

* Contravir Pharmaceuticals announces acceptance of clinical trial application in the United Kingdom

06 Sep 2017

BRIEF-ContraVir Pharmaceuticals announces issuance of new U.S. patent for expansion of cyclophilin inhibitor program

* ContraVir Pharmaceuticals announces issuance of new US patent for expansion of cyclophilin inhibitor program

21 Aug 2017

Earnings vs. Estimates